Fuchs Endothelial Corneal Dystrophy (FECD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Fuchs Endothelial Corneal Dystrophy (FECD) – Drugs In Development, 2024 report and make more profitable business decisions.
Fuchs endothelial corneal dystrophy (FECD) is characterized by progressive loss of corneal endothelial cells, thickening of Descement’s membrane and deposition of extracellular matrix in the form of guttae. When the number of endothelial cells becomes critically low, the cornea swells and causes loss of vision. It affects the thin layer of cells that line the back part of the cornea. This layer is called the endothelium. The disease occurs when these cells slowly start to die off. Symptoms iniclude reduction of corneal clarity, Nyctalopia, visual loss.
The Fuchs Endothelial Corneal Dystrophy (FECD) drugs in development market research report provide comprehensive information on the therapeutics under development for Fuchs Endothelial Corneal Dystrophy (FECD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fuchs Endothelial Corneal Dystrophy (FECD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Fuchs Endothelial Corneal Dystrophy (FECD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Fuchs Endothelial Corneal Dystrophy (FECD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Fuchs Endothelial Corneal Dystrophy (FECD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Fuchs Endothelial Corneal Dystrophy (FECD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ActualEyes IncAlcon Inc
Design Therapeutics Inc
Enzerna Biosciences LLC
Invirsa Inc
Kowa Co Ltd
Kuria Therapeutics Inc
Lee's Pharmaceutical Holdings Ltd
Medicibio Co Ltd
Prime Medicine Inc
Surrozen Inc
Trefoil Therapeutics LLC
University of Florida
Xequel Bio Inc
Yale University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Fuchs Endothelial Corneal Dystrophy (FECD) reports